Pharmacokinetics and 48-Week Safety and Antiviral Activity of Fosamprenavir-Containing Regimens in HIV-infected 2- To 18-Year-Old Children

Pediatric Infectious Disease Journal - United States
doi 10.1097/inf.0b013e3182a1126a